scholarly journals Lower heart failure and chronic kidney disease risks associated with sodium‐glucose cotransporter‐2 inhibitor use in Japanese type 2 diabetes patients without established cardiovascular and renal diseases

2021 ◽  
Vol 23 (S2) ◽  
pp. 19-27
Author(s):  
Issei Komuro ◽  
Takashi Kadowaki ◽  
Johan Bodegård ◽  
Marcus Thuresson ◽  
Suguru Okami ◽  
...  
Keyword(s):  
Heart Failure ◽  
Type 2 Diabetes ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Renal Diseases ◽  
Sodium Glucose Cotransporter ◽  
Disease Risks ◽  
Diabetes Patients

scholarly journals Sodium-glucose cotransporter 2 inhibitor effects on cardiovascular outcomes in chronic kidney disease

2020 ◽  
Vol 35 (Supplement_1) ◽  
pp. i43-i47 ◽  
Author(s):  
Oshini Shivakumar ◽  
Naveed Sattar ◽  
David C Wheeler
Keyword(s):  
Heart Failure ◽  
Type 2 Diabetes ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Major Adverse Cardiovascular Event ◽  
Sglt2 Inhibitors ◽  
Adverse Cardiovascular Event ◽  
Sodium Glucose Cotransporter ◽  
Patients With Heart Failure

Abstract Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce cardiovascular events, specifically those related to heart failure in patients with type 2 diabetes. Reductions in major adverse cardiovascular event (MACE) outcomes are also observed, but confined largely to patients who have prior cardiovascular disease. Cardiovascular outcome benefits extend to patients with type 2 diabetes and reduced estimated glomerular filtration (eGFR) rate down to 30 mL/min/1.73 m2 and to patients with heart failure but without diabetes. Ongoing trials are exploring whether patients with chronic kidney disease (CKD) but without diabetes will gain similar benefits from this class of agents. Although some safety concerns have emerged, it seems likely that SGLT2 inhibitors will be used more widely in CKD patients to reduce their cardiovascular risk.

Treatment Patterns in Type 2 Diabetes Patients with Chronic Kidney Disease-A Cohort Study

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 536-P
Author(s):  
MICHAEL BLANKENBURG ◽  
CSABA P. KOVESDY ◽  
SELINE EISENRING ◽  
ANNE FETT ◽  
EMILE W. SCHOKKER ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Chronic Kidney Disease ◽  
Cohort Study ◽  
Kidney Disease ◽  
Treatment Patterns ◽  
Diabetes Patients

1130-P: Mediators of the Effects of Canagliflozin (CANA) on Heart Failure (HF) and CV Death in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD)

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 1130-P
Author(s):  
JINGWEI LI ◽  
BRUCE NEAL ◽  
HIDDO L. HEERSPINK ◽  
CLARE ARNOTT ◽  
CHRISTOPHER CANNON ◽  
...  
Keyword(s):  
Heart Failure ◽  
Type 2 Diabetes ◽  
Chronic Kidney Disease ◽  
Kidney Disease

27-OR: Effect of Canagliflozin on Total Hospitalization for Heart Failure Events in Patients with Type 2 Diabetes and Chronic Kidney Disease

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 27-OR
Author(s):  
JINGWEI LI ◽  
MEG J. JARDINE ◽  
BRUCE NEAL ◽  
HIDDO L. HEERSPINK ◽  
CHRISTOPHER CANNON ◽  
...  
Keyword(s):  
Heart Failure ◽  
Type 2 Diabetes ◽  
Chronic Kidney Disease ◽  
Kidney Disease

scholarly journals Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over twenty years

2021 ◽  
Vol 32 ◽  
pp. 100739
Author(s):  
Claire A Lawson ◽  
Samuel Seidu ◽  
Francesco Zaccardi ◽  
Gerry McCann ◽  
Umesh T Kadam ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Heart Failure ◽  
Type 2 Diabetes ◽  
Chronic Kidney Disease ◽  
Type 2 Diabetes Mellitus ◽  
Kidney Disease ◽  
Failure Type ◽  
The Uk

The Role of DPP-4 Inhibitors in Type-2 Diabetes Patients with Chronic Kidney Disease

Pharmacophore ◽  
2021 ◽  
Vol 12 (3) ◽  
pp. 91-94
Author(s):  
Mishal Yousef Alqurashi ◽  
Khalid Faisal Alharthi ◽  
Abdulaziz Abdulrahman Alshehri ◽  
Yazeed Khalid Alharbi ◽  
Mohammad Abdulmunem Sanousi ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Diabetes Patients
Sign in / Sign up

Export Citation Format

Share Document